Our work provides foundational evidence for the potential therapeutic efficacy of CA and CGA in treating fatty liver and related metabolic disorders in laying hens via the activation of the ADPN-AMPK-PPARα pathway, and offers insights into the efficient utilization of CGA through targeted modification to CA. The gene discussed is PPARA; the disease is fatty liver disease.